Press Room

Oral and Inhalation Solid Dosage Forms Workshop

Start
Wednesday, March 27, 2019 - 00:00
End
Wednesday, March 27, 2019 - 00:00
Location: Switzerland
Oral Inhalation nasal Solid Dosage Forms | Hovione

 

Hovione is present at the Oral and Inhalation Solid Dosage Forms Workshop with a presentation by Maria Braga, Scientist of R&D Drug Product Development.

The workshop, organised at the MG2 premises on March Wednesday 27th, gives delegates the possibility to meet different industrial partners in a real market place; a place in which Academy and Industry can share their experiences and knowledge.



This event will last one day, divided in 2 different moments: speeches in the morning and workshop in the afternoon at MG2 Factory.

 

HOVIONE PRESENTATION

Title: From the engineered particle to lung deposition: how to successfully develop a carrier-based DPI?

Time: 9:30 am

Presenter: Maria Braga, Scientist of R&D Drug Product Development

 

 

If you would like to find more about Hovione's full range of inhalation drug development servicesparticle engineering and development by design schedule a meeting with us

Schedule a meeting button | Hovione

 

 

 

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026